Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ABT-335 Clear all
Completed Phase 3 Interventional Results available

Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

NCT00300456
View directory record Official record
Conditions
Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
Interventions
ABT-335, Simvastatin, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium

NCT00681395
View directory record Official record
Conditions
Adverse Events, Pharmacokinetic
Interventions
ABT-143, ABT-335, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

NCT00728910
View directory record Official record
Conditions
Dyslipidemia
Interventions
Atorvastatin, ABT335, ER Niacin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Between ABT-335, Rosuvastatin and Warfarin

NCT00487136
View directory record Official record
Conditions
Healthy
Interventions
Warfarin, warfarin plus ABT-335 plus rosuvastatin 5 mg, warfarin plus ABT-335 plus rosuvastatin 20 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 1 Interventional

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

NCT00585143
View directory record Official record
Conditions
Dyslipidemia, Renal Insufficiency
Interventions
ABT-335, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Gainesville, Florida • Miami, Florida • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

NCT00463606
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
ABT-335 and rosuvastatin calcium, ABT-335, rosuvastatin calcium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
168
States / cities
Birmingham, Alabama • Huntsville, Alabama • Ozark, Alabama + 135 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood

NCT00616772
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Heart Disease, Dyslipidemia
Interventions
ABT-335, Placebo, Atorvastatin
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
45 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
124
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

NCT00680017
View directory record Official record
Conditions
Dyslipidemia, Kidney Disease
Interventions
ABT-335 plus rosuvastatin, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
102
States / cities
Birmingham, Alabama • Huntsville, Alabama • Madison, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules

NCT00839293
View directory record Official record
Conditions
Healthy
Interventions
ABT-335
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium

NCT00808678
View directory record Official record
Conditions
Healthy
Interventions
ABT-143, ABT-335, rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

NCT00728780
View directory record Official record
Conditions
Adverse Events, Pharmacokinetic Variables
Interventions
ABT-143, ABT-335 and rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

NCT00300430
View directory record Official record
Conditions
Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
Interventions
ABT-335 and rosuvastatin calcium, ABT-335 and atorvastatin calcium, ABT-335 and simvastatin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2009 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

NCT00300482
View directory record Official record
Conditions
Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
Interventions
ABT-335, Rosuvastatin Calcium, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2009 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

NCT00639158
View directory record Official record
Conditions
Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
Interventions
ABT-335, placebo, atorvastatin, ezetimibe
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
118
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg

NCT00826358
View directory record Official record
Conditions
Healthy
Interventions
ABT-143, ABT-335, rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

NCT00300469
View directory record Official record
Conditions
Mixed Dyslipidemia, Coronary Heart Disease, Dyslipidemia
Interventions
ABT-335, Atorvastatin, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 17, 2026, 1:56 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Trilipix Effects on Lipids and Arteries

NCT01025492
View directory record Official record
Conditions
Dyslipidemia
Interventions
Trilipix, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe

NCT00681525
View directory record Official record
Conditions
Pharmacokinetics
Interventions
ABT-335, Atorvastatin, Ezetimibe
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study

NCT00673881
View directory record Official record
Conditions
Dyslipidemia
Interventions
choline fenofibrate
Drug
Lead sponsor
Radiant Research
Other
Eligibility
21 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

NCT00491530
View directory record Official record
Conditions
Mixed Dyslipidemia
Interventions
ABT-335, rosuvastatin calcium, simvastatin, atorvastatin calcium
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 17, 2026, 1:56 AM EDT